selected publications

• article

  • Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.  Annals of the Rheumatic Diseases.  76:346-354. 2017-01-01
    
  • A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.  Arthritis Research and Therapy.  18:-. 2016-01-01
    
  • Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.  Arthritis Research and Therapy.  18:-. 2016-01-01